Accessibility Menu
Astellas Pharma logo

Astellas Pharma(OTC) ALPMY

Current Price$13.21
Market Cap$23.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+81%
5 Year-11%
1 Year+34%
1 Month-1%
Astellas Pharma last closing stock price
MetricPriceDate
Last closeUSD 13.212026-07-24
Astellas Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.56%USD 13.282026-07-17
1 month-1.09%USD 13.352026-06-24
3 month-14.42%USD 15.432026-04-24
Year to date-0.64%USD 13.292025-12-31
1 year+34.39%USD 9.832025-07-24
3 year-0%USD 13.212023-07-25
5 year-11.44%USD 14.912021-07-23
Since inception+80.65%USD 7.312008-12-12

Astellas Pharma Financials at a Glance

Market Cap

$23.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.27T

Net Income (TTM)

¥309.12B

EPS (TTM)

$1.08

P/E Ratio

12.19

Dividend

$0.50

Beta (Volatility)

0.31 (Low)

Price

$13.21

Volume

141,228

Open

$13.19

Previous Close

$13.21

Daily Range

$13.19 - $13.27

52-Week Range

$9.91 - $17.35

Estimated Earnings Date

Aug 5, 2026

ALPMY News

MandA Deal

Why It's So Dang Hard to Value Biotech Deals

Brian Orelli, PhDMar 21, 2018
pfizer via facebook2

What Pfizer Gets in Its $14 Billion Medivation Deal

Todd CampbellAug 23, 2016
money inside pills flickr user chris potter

What Sent Medivation, Inc.'s Shares Soaring 25.1% In April

Todd CampbellMay 3, 2016
mdvn pipe

Sanofi's Bid for Medivation Is Too Low

Todd CampbellApr 28, 2016
johnsonandjohnson2

J&J's Q1 Results Suggest More Upside for Medivation, Inc.

Todd CampbellApr 27, 2016
bernie top

How Biotech Is Getting Berned by Sanders

Todd CampbellMar 31, 2016
take long view

Why Medivation Shares Are Tanking Today

Todd CampbellMar 29, 2016
Image by stevepb via pixabay copy 2

Medivation Inc. Stock Is Rising Today -- Here's Why

Brian FeroldiFeb 26, 2016
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company addresses critical unmet medical needs across various therapeutic areas, including oncology and urology.

Products and Services
  • Oncology treatments like XTANDI and PADCEV
  • Urological medications including Betanis and Vesicare
  • Immunosuppressants and antifungal agents
Growth Outlook
  • Strong pipeline with ongoing collaborations to enhance innovation
  • Recent partnerships with Merck and Harvard University for research
  • Focus on expanding therapeutic areas and product offerings
Financial Highlights
  • TTM revenue of 2.5 trillion JPY, reflecting robust market demand
  • Net income of 579.67 billion JPY in the latest quarter
  • Operating income margin of 17.59%, indicating operational efficiency
Astellas Pharma Inc. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that addresses significant health challenges. The company's commitment to research and development is evident through its strategic partnerships and innovative product pipeline. Recent financial performance highlights a strong revenue base and profitability, positioning Astellas for continued growth in the competitive healthcare landscape. The focus on expanding therapeutic areas and enhancing product offerings further underscores the company's potential for future success.
AI Generated • Jul 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, TY 103-8411, JP

ALPMY Financials

Key Financial Metrics (TTM)

Gross Margin

76.08%

Operating Margin

18.92%

Net Income Margin

13.63%

Return on Equity

17.44%

Return on Capital

21.33%

Return on Assets

8.17%

Earnings Yield

8.20%

Dividend Yield

3.75%

Payout Ratio

46.68%

Stock Overview

Market Cap

$23.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79B

Volume

141.23K

Avg. Volume

206.99K

Financials (TTM)

Gross Profit

¥1.69T

Operating Income

¥445.01B

EBITDA

¥445.01B

Operating Cash Flow

¥574.51B

Capital Expenditure

-¥58.44B

Free Cash Flow

¥516.06B

Cash & ST Invst.

¥282.83B

Total Debt

¥675.27B

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 11,210,593,310-2.8%
20242024-03-31JPY 11,104,729,504-0.9%
20252025-03-31JPY 12,543,905,53613.0%
20262026-03-31JPY 14,196,133,79713.2%
Astellas Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3010.1%
Q22025-09-305.5%
Q32025-12-319.0%
Q42026-03-3111.3%
Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.40-33.1%
20242024-03-31JPY 0.07-83.6%
20252025-03-31JPY 0.19182.3%
20262026-03-31JPY 1.08481.3%
Astellas Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-7.5%
Q22025-09-3018.1%
Q32025-12-3126.4%
Q42026-03-31-42.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥647.49B

+41.0%

Gross Profit

¥457.56B

+19.6%

Gross Margin

70.67%

N/A

Market Cap

$23.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.68M

N/A

Employees

14,099

N/A

Net Income

¥57.97B

-22.6%

EBITDA

-¥52.63B

-151.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥282.83B

+29.6%

Total Debt

¥675.27B

-18.8%

Accounts Receivable

¥765.07B

+21.0%

Inventory

¥332.45B

+11.8%

Long Term Debt

¥410.56B

-27.3%

Short Term Debt

¥264.71B

-0.7%

Return on Assets

8.17%

N/A

Return on Invested Capital

17.24%

N/A

Free Cash Flow

¥191.01B

+109.0%

Operating Cash Flow

¥207.50B

+105.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORINYOrion Oyj
$43.02+0.00%
WXXWYWuXi Biologics (Cayman) Inc.
$9.89+0.51%
WXIBFWuXi Biologics (Cayman) Inc.
$4.60+0.00%
SAUHFStraumann Holding AG
$118.30-2.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About ALPMY

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $13.21 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $9.91 and $17.35.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of ¥4.23B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported ¥1.77B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.75%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services